Search
Incannex Healthcare Inc
IXHLAdd to Watchlist
3.970USD
+0.260+7.01%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
54.32MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+7.01%
5 Days
+16.08%
1 Month
+28.48%
6 Months
-66.07%
Year to Date
-63.04%
1 Year
+1795.89%
Key Figures
3.740Open
4.025High
491.03KVolume
LossP/E TTM
387.20P/E Dynamic
--Dividend TTM
3.59%Turnover Ratio
3.710Prev. Close
3.710Low
1.33MTurnover
LossP/E Static
0.72P/B
0.00%Div Yield TTM
-100.36%ROA
49.80052wk High
2.76Volume Ratio
-46.88MNet Profit
13.68MShares
-17.1553EPS TTM
2.88Beta
-117.17%ROE
2.49052wk Low
8.49%Amplitude
100.00%Gross Margin
54.32MMarket Cap
2.47Reward/Risk
8.12%Risk Rate
TradingKey Stock Score of Incannex Healthcare Inc
Currency: USD Updated: 2026-07-02Key Insights
Incannex Healthcare Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered undervalued, ranking 88 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 18.00.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Incannex Healthcare Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Incannex Healthcare Inc Highlights
StrengthsRisks
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.
Growing
The company is in a growing phase, with the latest annual income totaling USD 86.00K.
Overvalued
The company’s latest PE is -0.23, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 501.46K shares, increasing 33.10% quarter-over-quarter.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
18.000
Target Price
+385.18%
Upside Space
Incannex Healthcare Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Incannex Healthcare Inc Info
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.
Ticker SymbolIXHL
CompanyIncannex Healthcare Inc
CEOLatham (Joel)
Website
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Incannex Healthcare Inc (IXHL)?
The current price of Incannex Healthcare Inc (IXHL) is 3.97.
What is the symbol of Incannex Healthcare Inc?
The ticker symbol of Incannex Healthcare Inc is IXHL.
What is the 52-week high of Incannex Healthcare Inc?
The 52-week high of Incannex Healthcare Inc is 49.80.
What is the 52-week low of Incannex Healthcare Inc?
The 52-week low of Incannex Healthcare Inc is 2.49.
What is the market capitalization of Incannex Healthcare Inc?
The market capitalization of Incannex Healthcare Inc is 54.32M.
Is Incannex Healthcare Inc (IXHL) currently rated as Buy, Hold, or Sell?
According to analysts, Incannex Healthcare Inc (IXHL) has an overall rating of Buy, with a price target of 18.00.
What is the Earnings Per Share (EPS TTM) of Incannex Healthcare Inc (IXHL)?
The Earnings Per Share (EPS TTM) of Incannex Healthcare Inc (IXHL) is -40.82.